ArticleIJID regions2026
Seroprevalence of hepatitis E in blood donors in Santiago, Chile: a monocentric cross-sectional study.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Hepatitis E virus (HEV) infection is emerging but under-recognized worldwide. However, the epidemiology and ecology of this infection in Chile are poorly understood. This study aimed to detect and analyze hepatitis E seroprevalence among blood donors at a private health care center in Santiago, Chile. Methods: Leftover sera were collected from 354 volunteer blood donors aged 18-65 years in July 2020. After recording sex, age, and municipality of residence, the specimens were anonymized and tested for anti-HEV immunoglobulin G antibodies using a commercial enzyme-linked immunosorbent assay kit (Wantai BioPharm). Municipalities were classified according to socioeconomic status as a proxy for income level. Statistical analyses were conducted using R software. Results: The overall seroprevalence was 15.3% (95% confidence interval, 11.9-19.4%). The prevalence increased significantly with age (50-65 years, 33.9%) and was higher among residents of lower-income municipalities than among those of higher-income municipalities (21.9% vs 11.7%). Multivariate analysis confirmed that age 50-65 years (odds ratio, 20.2) and residence in a lower-income municipality (odds ratio, 2.3) were independent predictors of HEV seropositivity. Conclusion: This study provides information on HEV exposure in adults in Santiago, Chile. Seroprevalence was highest in older age groups and among residents of lower-income municipalities. Further studies on HEV are needed to clarify its transmission cycle, circulating genotypes, and clinical relevance in Chile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.